ReviewHeart (British Cardiac Society)2019
Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy.
Review in Heart (British Cardiac Society), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05679206 (Association Between Preeclampsia, Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pressure, Systemic Arterial Pressure and Cardiovascular Function.), which is not on this map. Cited by 115 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Association Between Preeclampsia, Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pressure, Systemic Arterial Pressure and Cardiovascular Function.
Who cites it
115 citing papers in PubMed, 4 syntheses or guidelines pooled it, 238 citations in OpenAlex.
- A Systematic Review of Complications Following Pre-eclampsia.Maternal and child health journal · 2024Pooled it
- Prevention and Screening for Cardiometabolic Disease Following Hypertensive Disorders in Pregnancy in Low-Resource Settings: A Systematic Review and Delphi Study.Global heart · 2023Pooled it
- Primary Care-Based Cardiovascular Disease Risk Management After Adverse Pregnancy Outcomes: a Narrative Review.Journal of general internal medicine · 2022Pooled it
- Risk of type 2 diabetes mellitus in women with prior hypertensive disorders of pregnancy: a systematic review and meta-analysis.Diabetologia · 2021Pooled it
- The effect of a neonatal sleep intervention on maternal postpartum hypertension: a randomized trial.American journal of obstetrics & gynecology MFM · 2024Trial
- Be HealthInternational journal of environmental research and public health · 2020Trial
- Indigenous Health Disparities in Hypertensive Disorders of Pregnancy Within the United States.Current hypertension reports · 2026Review
- Optimizing the Postpartum Period to Support Lifelong Health for Women with Obesity.Current obesity reports · 2026Review
- Kampo Medicines Modulate Angiogenic, Antioxidant, and Inflammatory Pathways in Human Preclinical Models: Implications for Preeclampsia.Antioxidants (Basel, Switzerland) · 2026Article
- Impact of Blood Pressure Levels During Pregnancy on Postpartum Hypertensive Outcomes: Insights from a Cohort Study.Journal of clinical medicine · 2026Article
- Digital health interventions for hypertension in pregnant and perinatal women in low- and middle-income countries: a scoping review.BMC pregnancy and childbirth · 2026Article
- Peripartum cardiomyopathy: Clinical Predictors of favourable maternal-fetal outcomes.Pakistan journal of medical sciences · 2026Article
- Abnormal Pro-inflammatory Immune Cell Responses Precede Clinical Onset of Hypertensive Disorders of Pregnancy.Hypertension (Dallas, Tex. : 1979) · 2026Article
- COVID-19 vaccination during or just prior to pregnancy and hypertensive disorders of pregnancy.Vaccine · 2026Article
- Hypertensive Disorders of Pregnancy and Early-Life Cardiovascular Disease: Bridging the Knowledge Gap among Healthcare Providers.Current atherosclerosis reports · 2026Review
- Article
- Correlation between multi-parameter echocardiographic indicators and adverse pregnancy outcomes in women of advanced maternal age with pregnancy-induced hypertension syndrome: clinical application value.Frontiers in medicine · 2026Article
- Impact of Automated Insulin Delivery on Glycemic Profile and Maternal/Neonatal Outcomes in Pregnancy: A Review of the Evidence From Observational Studies.Journal of diabetes science and technology · 2026Review
- Role of epigenetic markers in cardiovascular disease following hypertensive disorders of pregnancy.Epigenomics · 2025Review
- Characteristics of lipid metabolism dysfunction in hypertensive disorders of pregnancy.BMC pregnancy and childbirth · 2025Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertensive disorders of pregnancy (HDP), such as gestational hypertension and pre-eclampsia, affect up to 10% of all pregnancies. These women have on average a twofold higher risk to develop cardiovascular disease (CVD) later in life as compared with women with normotensive pregnancies. This increased risk might result from an underlying predisposition to CVD, HDP itself or a combination of both. After pregnancy women with HDP show an increased risk of classical cardiovascular risk factors including chronic hypertension, renal dysfunction, dyslipidemia, diabetes and subclinical atherosclerosis. The prevalence and onset of cardiovascular risk factors depends on the severity of the HDP and the coexistence of other pregnancy complications. At present, guidelines addressing postpartum cardiovascular risk assessment for women with HDP show a wide variation in their recommendations. This makes cardiovascular follow-up of women with a previous HDP confusing and non-coherent. Some guidelines advise to initiate cardiovascular follow-up (blood pressure, weight and lifestyle assessment) 6-8 weeks after pregnancy, whereas others recommend to start 6-12 months after pregnancy. Concurrent blood pressure monitoring, lipid and glucose assessment is recommended to be repeated annually to every 5 years until the age of 50 years when women will qualify for cardiovascular risk assessment according to all international cardiovascular prevention guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.